Alumis Stock Crashes in Classic “Sell the News” After Strong Phase 3 Psoriasis Data
Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition.
/ 2 items
Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition.
Johnson & Johnson is reportedly discussing the purchase of Protagonist Therapeutics. This move could boost J&J's drug portfolio, especially in treatments for immune conditions and blood cancers.